Related Experiment Videos
Chemosensitivity of murine renal carcinoma
Abstract:
A non-endocrine dependent, spontaneous carcinoma of the kidney in a Wistar-Lewis rat has been studied for sensitivity to chemotherapeutic agents. Two tumour models have been employed. Subcutaneously transplanted flank nodules were used to screen single agents for antitumour activity.. A model of intraperitoneal metastatic disease was employed to test further agents which had demonstrated some effectiveness in the nodule model. Single agents that proved ineffective were streptozotocin, neocarzinostatin, chlorozotocin and carminomycin. 5-FU, bleomycin and hydroxyurea were also ineffective at the doses tested. Agents that were effective included cyclophosphamide, adriamycin, vinblastine, vindesin and maytansine. The most effective combination therapy appeared to be cyclophosphamide with vindesin and cisplatin.
Insights
This study screened kidney carcinoma in rats against chemotherapy. Cyclophosphamide combined with vindesin and cisplatin showed the most promise for treating this non-endocrine dependent cancer.
Area of Science:
- Oncology
- Pharmacology
- Animal Models
Background:
- Non-endocrine dependent kidney carcinoma in Wistar-Lewis rats was utilized.
- This spontaneous tumor model offers a unique system for chemotherapy research.
Purpose of the Study:
- To evaluate the efficacy of various chemotherapeutic agents against kidney carcinoma.
- To identify effective single agents and combination therapies for potential clinical application.
Main Methods:
- Two tumor models were employed: subcutaneous nodules for initial screening and intraperitoneal metastatic disease for further testing.
- Agents screened included streptozotocin, neocarzinostatin, 5-fluorouracil (5-FU), bleomycin, hydroxyurea, cyclophosphamide, adriamycin, vinblastine, vindesin, maytansine, and cisplatin.
Main Results:
- Streptozotocin, neocarzinostatin, chlorozotocin, carminomycin, 5-FU, bleomycin, and hydroxyurea were ineffective at tested doses.
- Cyclophosphamide, adriamycin, vinblastine, vindesin, and maytansine demonstrated antitumour activity.
- The combination of cyclophosphamide with vindesin and cisplatin was the most effective therapeutic strategy.
Conclusions:
- Several chemotherapeutic agents show potential for treating non-endocrine dependent kidney carcinoma.
- Combination therapy, particularly cyclophosphamide, vindesin, and cisplatin, warrants further investigation for efficacy in kidney cancer treatment.